Home Cart Sign in  
Chemical Structure| 1821-12-1 Chemical Structure| 1821-12-1

Structure of 4-Phenylbutyric acid
CAS No.: 1821-12-1

Chemical Structure| 1821-12-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4-Phenylbutanoic acid is an inhibitor of HDAC which can regulate gene transcription with anti-tumor and neuroprotective effects.

Synonyms: 4-PBA; Benzenebutyric acid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Griffin, Matthew E. ; Tsukidate, Taku ; Hang, Howard C. ;

Abstract: The characterization of microbiota mechanisms in health and disease has reinvigorated pattern recognition receptors as prominent targets for immunotherapy. Notably, our recent studies on Enterococcus species revealed peptidoglycan remodeling and activation of NOD2 as key mechanisms for microbiota enhancement of immune checkpoint inhibitor therapy. Inspired by this work and other studies of NOD2 activation, we performed in silico ligand screening and developed N-arylpyrazole dipeptides as novel NOD2 agonists. Importantly, our N-arylpyrazole NOD2 agonist is enantiomer-specific and effective at promoting immune checkpoint inhibitor therapy and requires NOD2 for activity in vivo. Given the significant functions of NOD2 in innate and adaptive immunity, these next-generation agonists afford new therapeutic leads and adjuvants for a variety of NOD2-responsive diseases.

Purchased from AmBeed: ; ; ; ; ;

Alternative Products

Product Details of 4-Phenylbutyric acid

CAS No. :1821-12-1
Formula : C10H12O2
M.W : 164.20
SMILES Code : O=C(O)CCCC1=CC=CC=C1
Synonyms :
4-PBA; Benzenebutyric acid
MDL No. :MFCD00004403
InChI Key :OBKXEAXTFZPCHS-UHFFFAOYSA-N
Pubchem ID :4775

Safety of 4-Phenylbutyric acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of 4-Phenylbutyric acid

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MHCC-LM3 cells 0, 1, 5, 10 mM 24 h Measure Wnt5b expression and secretion Clin Transl Med. 2021 Apr;11(4):e379.
Huh7 cells 0, 1, 5, 10 mM 24 h Measure Wnt5b expression and secretion Clin Transl Med. 2021 Apr;11(4):e379.
human peripheral blood mononuclear cells 1 mM 2 days 4-PBA-treated human monocytes significantly reduced ICAM-1 expression and increased CD24 expression. Circ Res. 2024 Sep 27;135(8):856-872.
mouse bone marrow-derived monocytes 1 mM 5 days 4-PBA-treated monocytes exhibited anti-inflammatory characteristics, reducing ICAM-1 expression and increasing CD24 expression. Circ Res. 2024 Sep 27;135(8):856-872.
bEnd.3 cells 0-10 mM 96 h To investigate the effect of 4-PBA on LACV infection, results showed that 4-PBA treatment significantly reduced LACV infection and increased host cell survival. Nat Commun. 2023 May 18;14(1):2836.
HK-2 cells 5 μM 24 h 4-PBA treatment alleviated oxalate-induced oxidative injury and ferroptosis in HK-2 cells, including restoring GSH content, suppressing Fe2+ and lipid peroxidation accumulation, and regulating ferroptosis-related proteins. Adv Sci (Weinh). 2025 Mar;12(10):e2403992.
293T cells 10 mM 48 h Alleviated DFO-induced Grp78 expression and improved LAMP1 maturation, reduced DFO-induced LC3B-II accumulation Redox Biol. 2022 Sep;55:102407.
Mouse pulmonary artery smooth muscle cells 1 mM 24 h Pretreatment with 4-PBA significantly reduced hypercontractility in TgNotch3R169C pulmonary arteries and restored it to TgNotch3WT levels. Hypertension. 2023 Aug;80(8):1683-1696.
VSMCs 1mM 24h To investigate the role of ER stress in ROS generation in SHR VSMCs, the results showed that 4-PBA reduced ROS levels in SHR cells Hypertension. 2018 Jul;72(1):235-246.
Chondrocytes from G610C OI mice 5 mM 24 h 4PBA treatment significantly increased the expression levels of hypertrophy-related genes, suggesting that reduction of cell stress rescued the suppressed maturation of G610C OI chondrocytes JCI Insight. 2022 Feb 8;7(3):e149636.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice High-fat diet-induced ApoE−/− mouse model Intraperitoneal injection 100 mg/kg Every 3 days for an additional 4 weeks 4-PBA injection significantly reduced atherosclerotic plaque size and lipid deposition, and increased plaque collagen content. Circ Res. 2024 Sep 27;135(8):856-872.
Mice LACV-infected mouse model Intraperitoneal injection 500 mg/kg Once daily for 5 days To investigate the inhibitory effect of 4-PBA on LACV-induced neurological disease, results showed that 4-PBA treatment delayed the development of neurological disease. Nat Commun. 2023 May 18;14(1):2836.
KM mice CaOx kidney stone model Intraperitoneal injection 20 mg/kg Once daily for 14 days 4-PBA treatment alleviated ferroptosis, improved renal function, and reduced crystal deposition in CaOx kidney stone models. Adv Sci (Weinh). 2025 Mar;12(10):e2403992.
C57BL/6 mice DEN-induced HCC model In drinking water 1.0 g/kg For 4 months Evaluate the effect of 4-PBA on HCC development Clin Transl Med. 2021 Apr;11(4):e379.
Mice TgNotch3R169C mice 1 mmol/L Single pretreatment Pretreatment with 4-PBA significantly improved hypercontractility and vasorelaxation in pulmonary arteries of TgNotch3R169C mice. Hypertension. 2023 Aug;80(8):1683-1696.
Mice G610C OI mice Intraperitoneal injection 0.4 mg Daily for 10 days 4PBA treatment significantly improved the osteoblastic transition and translocation of hypertrophic chondrocytes in G610C OI mice, though not quite to the WT level JCI Insight. 2022 Feb 8;7(3):e149636.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.09mL

1.22mL

0.61mL

30.45mL

6.09mL

3.05mL

60.90mL

12.18mL

6.09mL

References

 

Historical Records

Categories